Authors

Latest:

A Miracle Maker in Pediatric Hematologic Cancers

A love of collaborating with colleagues from around the globe and a fiery passion to help children diagnosed with cancer led Ching-Hon Pui, MD, to dramatically improve outcomes in pediatric oncology.

Bartosz Chmielowski, MD

Latest:

Dr Chmielowski on the Rationale for Investigating Oncolytic Viruses in Melanoma

Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.

Sarah Lynam, MD

Sarah Lynam, MD, is an assistant professor in the Division of Gynecologic Oncology in the Department of Reproductive Biology at Case Western Reserve University School of Medicine and an attending physician in the Division of Gynecologic Oncology at the Seidman Cancer Center at the University Hospitals Cleveland Medical Center in Ohio.

Latest:

Dr Lynam on the Clinical Implications of Targeted Therapies in Ovarian Cancer

Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.

Radhika Poojari, PhD

Latest:

Cetuximab–Radionuclide Functionalized Polymeric Nanocomplexes: A Radiopharmaceutical Perspective for Liver Cancer

Liver cancer is a highly vascularized and one of the most drug resistant forms of solid tumors.

Robin Foa, MD, Sapienza University

Latest:

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

Elizabeth Lee, MD

Latest:

Dr Lee on the Future Development of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Alessandra Larocca, MD, PhD

Latest:

Dr. Larocca on Recent Advancements in R/R Multiple Myeloma

Alessandra Larocca, MD, PhD, discusses recent advancements in relapsed/refractory multiple myeloma.

Chau Dang, MD, Memorial Sloan Kettering Westchester

Latest:

Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast Cancer

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

Michelle Monje, MD, PhD

Michelle Monje, MD, PhD, is the Milan Gambhir Professor of Pediatric Neuro-Oncology and a professor by courtesy of neurosurgery, pediatrics, pathology, and psychiatry and behavioral sciences at Stanford University, as well as a member of the Institute for Stem Cell Biology and Regenerative Medicine, the Maternal & Child Health Research Institute, the Wu Tsai Neurosciences Institute, and the Stanford Cancer Institute in Palo Alto, California.

Latest:

Dr Monje on the Role of a Novel GD2-Directed CAR T-Cell Therapy in Diffuse Midline Glioma

Michelle Monje, MD, PhD, discusses the early efficacy of a novel GD2-directed CAR T-cell therapy for the treatment of children with diffuse midline glioma.

Kyle Lowry

Elena Elimova, MD

Elena Elimova, MD, is an Associate Professor, Department of Medicine, University of Toronto, Staff Medical Oncologist, Princess Margaret Hospital.

Latest:

Dr Elimova on the Efficacy of Zanidatamab With Chemotherapy in HER2+ Advanced/Metastatic Gastroesophageal Adenocarcinoma

Elena Elimova, MD, discusses the efficacy of zanidatamab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma.

Brian M. Andersen, MD, PhD

Latest:

Will Immunotherapy Become a Standard of Care for Glioblastoma?

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

Tara Berman, MD, MS

Tara Berman, MD, MS, is a medical oncologist at Dana-Farber Cancer Institute and a member of faculty at Harvard Medical School in Boston, Massachusetts.

Latest:

Optimizing Therapy for MMR-Proficient Endometrial Cancer

Panelists discuss how the DUO trial demonstrates the benefit of durvalumab in adjuvant endometrial cancer treatment and suggests potential value of adding olaparib in specific subgroups like mismatch repair–proficient patients, though emphasizing the need for confirmatory studies before routine clinical implementation.

Mary Anne Fenton, MD

Latest:

Dr Fenton on Findings from the DESTINY-Breast02 Trial in HER2+ Breast Cancer

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Yoshie Umemura, MD

Latest:

Dr Umemura on the Development of ONC201 in H3K27M-Mutant Diffuse Midline Glioma

Yoshie Umemura, MD, discusses the development of ONC201 in patients with H3K27M-mutated diffuse midline glioma.

Sankalp Arora, MD

Sankalp Arora, MD, is a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center.

Latest:

Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML

Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.

Akshat Jain, MBBS

Latest:

Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding Disorders

Akshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

Leif Stenke, MD, PhD

Latest:

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

Dr Leif Stenke reviews data on XS004 in patients with chronic myeloid leukemia (CML) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

Kristin G. Anderson, PhD

Latest:

Dr. Anderson on Overcoming Suppressive Signals by Engineering T-cells in Ovarian Cancer

Kristin G. Anderson, PhD, discusses overcoming suppressive signaling by engineering T-cells in ovarian cancer.

Qian (Janie) Qin, MD

Latest:

Dr Qin on the Design of the HARMONY Trial of Niraparib-Based Therapy in mHSPC

Qian (Janie) Qin, MD, discusses the unique design of the phase 2 HARMONY trial of first-line niraparib plus abiraterone acetate and prednisone in mHSPC.